ClinicalTrials.gg
CompletedNCT00920816Updated May 6, 2022Results posted

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

A Phase 3 interventional study of Axitinib (AG-013736) and Sorafenib in Kidney Neoplasms, sponsored by Pfizer. Completed at 125 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-06.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
492
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing axitinib in Kidney Neoplasms — 3 open to participants now, 3 under way, 1 of them phase 3. Axitinib · Kidney Neoplasms.

Enrollment
4th of 12
492 · median 54
Started
2009
with 1 other
Phase 3
4 of 12
1 open now
Registered
4th of 12
by date
Lead sponsor
5 of 12
Pfizer

Among the 12 studies testing axitinib in Kidney Neoplasms, this one is the 4th largest by enrollment, is one of 2 that started in 2009, is one of 4 in phase 3, and was the 4th registered.

Kidney Neoplasms

969 studies on the registry are indexed under Kidney Neoplasms; 210 are open to participants now.

Browse Kidney Neoplasms studies →

Open to participants now

3 of the 12 studies testing axitinib in Kidney Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About axitinib

Axitinib: first FDA approval 2012 (INLYTA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Kidney Neoplasms studies recruiting now, 133 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing axitinib in Kidney Neoplasms, or all of them as a file.
02

Study summary

The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer.

03

Conditions studied

  • Kidney Neoplasms

Browse trials for

Keywords

  • Axitinib in First & Second Line Treatment of Patients With Metastatic Renal Cell Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented renal cell cancer with a component of clear cell histology.
  • Evidence of .
  • Patients with mRCC must have received no prior systemic therapy or must have progressive disease per (version 1.0) after one prior systemic first line regimen for metastatic disease containing sunitinib, cytokine(s), or both.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment for renal cell cancer with more that one systemic therapy.
  • Major surgery less that 4 weeks or radiation less than 2 weeks of starting study drug.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Masking
None (open label)
Enrollment
492 participants (actual)

Study arms

  • Experimental
    A

    Drug: Axitinib (AG-013736)

  • Active comparator
    B

    Drug: Sorafenib

Interventions

  • axitinib will be given at a starting dose of 5 mg BID with continuous dosing

  • sorafenib will be given at a dose of 400 mg BID continuous dosing

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS): First-Line Participants

    Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease \[PD\]), or from adverse event (AE) data (where outcome was "Death"). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is \>= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.

    Time frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)

  2. Progression Free Survival (PFS): Second-Line Participants

    Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease \[PD\]), or from adverse event (AE) data (where outcome was "Death"). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is \>= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.

    Time frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)

Secondary outcomes

  1. Percentage of Participants With Objective Response (OR): First-Line Participants

    Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.

    Time frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)

  2. Percentage of Participants With Objective Response (OR): Second-Line Participants

    Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.

    Time frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)

  3. Duration of Response (DR): First-Line Participants

    Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)

  4. Duration of Response (DR): Second-Line Participants

    Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)

  5. Overall Survival (OS): First-Line Participants

    Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

    Time frame: Baseline until death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)

  6. Overall Survival (OS): Second-Line Participants

    Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

    Time frame: Baseline until death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)

Other outcomes

  1. Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): First-Line Participants

    FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).

    Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)

  2. Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): Second-Line Participants

    FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).

    Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)

  3. Functional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): First-Line Participants

    FKSI-DRS: subset of FKSI which is FACT-Kidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).

    Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)

  4. Functional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): Second-Line Participants

    FKSI-DRS: subset of FKSI which is FACT-Kidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).

    Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)

  5. Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: First-Line Participants

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)

  6. Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: Second-Line Participants

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)

  7. Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): First-Line Participants

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.

    Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)

  8. Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): Second-Line Participants

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.

    Time frame: Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)

07

Results

Posted Feb 4, 2014
Limitations and caveats
The objective of the statistical analysis for secondary endpoints was to summarize data using descriptive statistics without performing any hypothesis testing. Safety analysis did not include data from all China participants due to inability to obtain timely approval to use data in accordance to HGRAC regulations.

Participant flow

First-line participants included all treatment-naive participants with metastatic renal cell cancer (mRCC) from global and second-line participants included all previously-treated Asian participants with mRCC.

Participant flow — Overall Study
MilestoneAxitinib (First-line Participants)Sorafenib (First-line Participants)Axitinib (Second-line Participants)Sorafenib (Second-line Participants)
Started1929613569
Treated1899613569
Participants from china (excluded from safety analysis)16812464
Completed0000
Not completed1929613569
Withdrew: Death1166383
Withdrew: Participant refused continued treatment for reason other than adverse events11510
Withdrew: Global deterioration of health status2000
Withdrew: Objective progression or relapse6200
Withdrew: Other261512
Withdrew: Lost to follow-up11200
Withdrew: Adverse event1110
Withdrew: Data not disclosed due to lack of hgrac filings16812464
Withdrew: Randomized but not treated3000

Outcome measures

PrimaryProgression Free Survival (PFS): First-Line Participants

Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease \[PD\]), or from adverse event (AE) data (where outcome was "Death"). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is \>= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.

Time frame:
Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)
Reported as:
Median · months
Progression Free Survival (PFS): First-Line Participants
monthsAxitinib (First-line Participants)Sorafenib (First-line Participants)
Progression Free Survival (PFS): First-Line Participants10.1 (7.2 to 12.1)6.5 (4.7 to 8.3)
Statistical analysis
  • Axitinib (First-line Participants) vs Sorafenib (First-line Participants) · Hazard ratio (hr): 0.767 · 95% CI 0.559 to 1.053
PrimaryProgression Free Survival (PFS): Second-Line Participants

Time in months from randomization to first documentation of objective tumor progression or death due to any cause. PFS calculated as (first event date minus date of randomization plus 1)/30.4. Tumor progression determined from oncologic assessment data (where it meets criteria for progressive disease \[PD\]), or from adverse event (AE) data (where outcome was "Death"). Progression using Response Evaluation Criteria in Solid Tumors (RECIST) is \>= 20 percent (%) increase in sum of longest diameter of target lesions; measurable increase in non-target lesion; appearance of new lesions.

Time frame:
Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)
Reported as:
Median · months
Progression Free Survival (PFS): Second-Line Participants
monthsAxitinib (Second-line Participants)Sorafenib (Second-line Participants)
Progression Free Survival (PFS): Second-Line Participants6.5 (4.7 to 9.1)4.8 (3.0 to 6.5)
Statistical analysis
  • Axitinib (Second-line Participants) vs Sorafenib (Second-line Participants) · Hazard ratio (hr): 0.731 · 95% CI 0.506 to 1.058
SecondaryPercentage of Participants With Objective Response (OR): First-Line Participants

Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.

Time frame:
Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR): First-Line Participants
percentage of participantsAxitinib (First-line Participants)Sorafenib (First-line Participants)
Percentage of Participants With Objective Response (OR): First-Line Participants32.3 (25.7 to 39.4)14.6 (8.2 to 23.3)
SecondaryPercentage of Participants With Objective Response (OR): Second-Line Participants

Percentage of participants with OR based on assessment of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST. Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR was defined as disappearance of all lesions (target and/or non target). PR were those with at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.

Time frame:
Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR): Second-Line Participants
percentage of participantsAxitinib (Second-line Participants)Sorafenib (Second-line Participants)
Percentage of Participants With Objective Response (OR): Second-Line Participants23.7 (16.8 to 31.8)10.1 (4.2 to 19.8)
SecondaryDuration of Response (DR): First-Line Participants

Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)
Reported as:
Median · months
Duration of Response (DR): First-Line Participants
monthsAxitinib (First-line Participants)Sorafenib (First-line Participants)
Duration of Response (DR): First-Line Participants14.7 (11.0 to NA)14.3 (11.3 to NA)
SecondaryDuration of Response (DR): Second-Line Participants

Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
Baseline until disease progression or death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)
Reported as:
Median · months
Duration of Response (DR): Second-Line Participants
monthsAxitinib (Second-line Participants)Sorafenib (Second-line Participants)
Duration of Response (DR): Second-Line ParticipantsNA (12.5 to NA)8.7 (4.1 to NA)
SecondaryOverall Survival (OS): First-Line Participants

Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

Time frame:
Baseline until death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 107)
Reported as:
Median · months
Overall Survival (OS): First-Line Participants
monthsAxitinib (First-line Participants)Sorafenib (First-line Participants)
Overall Survival (OS): First-Line ParticipantsNA (18.1 to NA)NA (18.1 to NA)
SecondaryOverall Survival (OS): Second-Line Participants

Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).

Time frame:
Baseline until death (assessed on Week 6, Week 12 and thereafter every 8 weeks up to Week 103)
Reported as:
Median · months
Overall Survival (OS): Second-Line Participants
monthsAxitinib (Second-line Participants)Sorafenib (Second-line Participants)
Overall Survival (OS): Second-Line Participants17.2 (14.8 to NA)18.1 (12.1 to NA)
Other pre-specifiedFunctional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): First-Line Participants

FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).

Time frame:
Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)
Reported as:
Mean · units on a scale
Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): First-Line Participants
units on a scaleAxitinib (First-line Participants)Sorafenib (First-line Participants)
C1 D143.869 ± 8.11743.865 ± 6.723
C2 D143.328 ± 7.63043.969 ± 6.286
C3 D143.366 ± 7.19243.345 ± 6.878
C4 D142.932 ± 7.56642.926 ± 7.324
C5 D143.211 ± 7.57844.022 ± 6.714
C6 D142.787 ± 8.09842.344 ± 6.685
C7 D142.474 ± 7.92643.446 ± 6.931
C8 D142.534 ± 7.51044.077 ± 6.986
C9 D142.778 ± 8.22944.051 ± 7.234
C10 D143.120 ± 7.96644.018 ± 6.751
C11 D143.264 ± 7.83745.000 ± 6.130
C12 D143.962 ± 7.24345.318 ± 6.440
C13 D144.141 ± 7.28945.787 ± 6.526
C14 D143.789 ± 7.98545.459 ± 6.535
C15 D144.176 ± 8.05545.514 ± 5.914
C16 D144.232 ± 7.51546.000 ± 5.651
C17 D143.897 ± 8.45646.400 ± 6.262
C18 D143.761 ± 8.01945.357 ± 6.983
C19 D143.737 ± 7.41345.583 ± 7.366
C20 D143.733 ± 7.60544.333 ± 7.066
C21 D145.417 ± 6.24043.500 ± 7.687
C22 D147.000 ± 5.98545.833 ± 5.937
C23 D147.571 ± 6.35745.714 ± 6.651
End of treatment39.052 ± 9.10939.524 ± 8.896
Follow-up39.683 ± 11.13240.038 ± 9.897
Other pre-specifiedFunctional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): Second-Line Participants

FKSI-15 questionnaires (lack of energy, side effects, pain, weight loss, bone pain, fatigue, enjoying life, short of breath, worsened condition, appetite, coughing, bothered by fevers, ability to work, hematuria, sleep) was used to assess quality of life (QoL) for those diagnosed with renal cell cancer. Questions answered on 5-point Likert scale: 0 to 4 (0= not at all, 1= little bit, 2= somewhat, 3= quite a bit, 4= very much). Total FKSI score 0 to 60; higher scores=better health states (Individual questions may be reversed coded, as appropriate).

Time frame:
Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)
Reported as:
Mean · units on a scale
Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15): Second-Line Participants
units on a scaleAxitinib (Second-line Participants)Sorafenib (Second-line Participants)
C1 D146.753 ± 6.69247.470 ± 7.450
C2 D146.217 ± 7.02845.045 ± 7.478
C3 D145.968 ± 7.23745.684 ± 7.756
C4 D145.060 ± 8.04045.792 ± 7.762
C5 D145.775 ± 7.79746.125 ± 7.491
C6 D145.407 ± 7.27446.341 ± 7.213
C7 D145.709 ± 8.26345.053 ± 7.843
C8 D145.169 ± 7.60945.676 ± 9.357
C9 D145.829 ± 7.44245.970 ± 8.487
C10 D145.608 ± 8.29946.148 ± 8.156
C11 D145.833 ± 7.59947.227 ± 6.611
C12 D145.797 ± 6.96748.091 ± 6.414
C13 D146.727 ± 7.30747.600 ± 5.762
C14 D147.740 ± 7.09449.133 ± 5.235
C15 D148.023 ± 6.29749.308 ± 4.111
C16 D148.184 ± 6.18650.500 ± 3.989
C17 D147.909 ± 6.86649.000 ± 5.869
C18 D148.138 ± 6.79149.125 ± 5.139
C19 D148.636 ± 5.20648.571 ± 7.458
C20 D148.810 ± 6.47850.500 ± 4.637
C21 D150.188 ± 5.58850.000 ± 5.177
End of treatment41.432 ± 9.18842.889 ± 8.846
Follow-up35.385 ± 7.79538.583 ± 11.556
Other pre-specifiedFunctional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): First-Line Participants

FKSI-DRS: subset of FKSI which is FACT-Kidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).

Time frame:
Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)
Reported as:
Mean · units on a scale
Functional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): First-Line Participants
units on a scaleAxitinib (First-line Participants)Sorafenib (First-line Participants)
C1 D128.691 ± 5.39229.653 ± 4.699
C2 D128.728 ± 4.58129.963 ± 3.817
C3 D1 (29.171 ± 4.09329.750 ± 4.095
C4 D128.577 ± 4.30529.642 ± 4.244
C5 D129.020 ± 4.25730.255 ± 3.668
C6 D128.574 ± 4.67429.153 ± 4.009
C7 D128.568 ± 4.54829.523 ± 4.051
C8 D128.557 ± 4.30830.296 ± 3.890
C9 D128.817 ± 4.66530.186 ± 4.392
C10 D129.057 ± 4.48430.364 ± 4.143
C11 D129.146 ± 4.20730.688 ± 3.926
C12 D129.648 ± 3.75230.727 ± 3.896
C13 D129.545 ± 4.05631.483 ± 3.602
C14 D129.579 ± 4.18631.027 ± 3.790
C15 D129.859 ± 4.43830.730 ± 3.724
C16 D129.683 ± 4.24231.515 ± 3.242
C17 D129.564 ± 4.69531.567 ± 3.884
C18 D129.380 ± 4.75231.107 ± 4.425
C19 D129.737 ± 4.41431.417 ± 3.911
C20 D129.844 ± 4.52730.762 ± 4.122
C21 D130.889 ± 3.11530.056 ± 4.372
C22 D131.696 ± 3.08131.000 ± 3.275
C23 D131.357 ± 3.38831.143 ± 4.413
End of treatment26.556 ± 5.48726.786 ± 5.982
Follow-up26.805 ± 6.37326.769 ± 6.095
Other pre-specifiedFunctional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): Second-Line Participants

FKSI-DRS: subset of FKSI which is FACT-Kidney Symptom Index questionnaire used to assess QoL for participants diagnosed with renal cell cancer. FKSI contains 15 questions and FKSI-DRS 9 questions (lack of energy, pain, losing weight, bone pain, fatigue, short of breath, coughing, bothered by fevers, hematuria) each ranging from 0 (not at all) to 4 (very much). FKSI-DRS total score 0 to 36; higher scores associated with better health states (Individual questions may be reversed coded, as appropriate).

Time frame:
Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)
Reported as:
Mean · units on a scale
Functional Assessment of Cancer Therapy Kidney Symptom Index -Disease Related Symptoms (FKSI-DRS): Second-Line Participants
units on a scaleAxitinib (Second-line Participants)Sorafenib (Second-line Participants)
C1 D131.020 ± 3.98631.489 ± 4.538
C2 D130.600 ± 3.89230.682 ± 3.895
C3 D130.645 ± 3.68130.965 ± 3.803
C4 D130.103 ± 4.55830.679 ± 3.980
C5 D130.676 ± 4.27131.063 ± 3.629
C6 D130.731 ± 3.97331.439 ± 4.249
C7 D130.920 ± 4.37330.632 ± 4.365
C8 D130.966 ± 4.14430.703 ± 5.195
C9 D131.012 ± 3.78330.667 ± 4.884
C10 D130.986 ± 4.13330.926 ± 4.215
C11 D131.212 ± 4.03332.045 ± 3.579
C12 D131.356 ± 3.44332.000 ± 3.338
C13 D131.418 ± 3.77532.100 ± 2.989
C14 D132.100 ± 3.32132.800 ± 2.274
C15 D132.000 ± 2.86132.769 ± 2.279
C16 D131.921 ± 3.37233.167 ± 2.167
C17 D132.061 ± 3.34432.800 ± 2.898
C18 D131.931 ± 3.11632.625 ± 2.615
C19 D132.364 ± 2.34132.429 ± 4.429
C20 D131.905 ± 2.99833.500 ± 2.168
C21 D133.125 ± 2.47333.500 ± 2.345
End of treatment28.216 ± 5.66229.519 ± 4.661
Follow-up24.692 ± 4.36627.500 ± 6.762
Other pre-specifiedEuro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: First-Line Participants

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

Time frame:
Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)
Reported as:
Mean · units on a scale
Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: First-Line Participants
units on a scaleAxitinib (First-line Participants)Sorafenib (First-line Participants)
C1 D10.710 ± 0.2540.712 ± 0.272
C2 D10.709 ± 0.2140.693 ± 0.237
C3 D10.694 ± 0.2510.687 ± 0.261
C4 D10.696 ± 0.2350.668 ± 0.265
C5 D10.708 ± 0.2210.673 ± 0.269
C6 D10.683 ± 0.2630.641 ± 0.281
C7 D10.685 ± 0.2250.676 ± 0.255
C8 D10.678 ± 0.2740.717 ± 0.244
C9 D10.704 ± 0.2390.729 ± 0.202
C10 D10.682 ± 0.2770.723 ± 0.238
C11 D10.698 ± 0.2600.748 ± 0.199
C12 D10.708 ± 0.2270.742 ± 0.218
C13 D10.708 ± 0.2530.761 ± 0.220
C14 D10.703 ± 0.2600.731 ± 0.254
C15 D10.689 ± 0.2690.755 ± 0.225
C16 D10.702 ± 0.2440.775 ± 0.186
C17 D10.706 ± 0.2500.738 ± 0.250
C18 D10.699 ± 0.2590.777 ± 0.191
C19 D10.713 ± 0.2560.762 ± 0.261
C20 D10.699 ± 0.2610.710 ± 0.300
C21 D10.712 ± 0.2320.702 ± 0.307
C22 D10.737 ± 0.2550.774 ± 0.177
C23 D10.736 ± 0.2750.789 ± 0.187
End of treatment0.635 ± 0.2680.588 ± 0.291
Follow-up0.545 ± 0.4340.618 ± 0.254
Other pre-specifiedEuro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: Second-Line Participants

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

Time frame:
Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)
Reported as:
Mean · units on a scale
Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Index Score: Second-Line Participants
units on a scaleAxitinib (Second-line Participants)Sorafenib (Second-line Participants)
C1 D10.812 ± 0.2250.831 ± 0.186
C2 D10.769 ± 0.2180.754 ± 0.251
C3 D10.772 ± 0.2060.755 ± 0.278
C4 D10.737 ± 0.2720.759 ± 0.211
C5 D10.780 ± 0.2030.768 ± 0.275
C6 D10.767 ± 0.2510.753 ± 0.245
C7 D10.762 ± 0.2520.768 ± 0.239
C8 D10.758 ± 0.2410.733 ± 0.339
C9 D10.796 ± 0.2030.794 ± 0.262
C10 D10.768 ± 0.2430.820 ± 0.169
C11 D10.792 ± 0.2100.848 ± 0.158
C12 D10.797 ± 0.2010.837 ± 0.157
C13 D10.786 ± 0.2170.814 ± 0.156
C14 D10.833 ± 0.1620.871 ± 0.131
C15 D10.819 ± 0.1510.829 ± 0.152
C16 D10.811 ± 0.1860.828 ± 0.142
C17 D10.834 ± 0.1580.865 ± 0.122
C18 D10.830 ± 0.1640.829 ± 0.160
C19 D10.830 ± 0.1480.861 ± 0.139
C20 D10.832 ± 0.1630.923 ± 0.129
C21 D10.859 ± 0.1550.852 ± 0.176
End of treatment0.582 ± 0.4060.623 ± 0.296
Follow-up0.429 ± 0.3580.418 ± 0.565
Other pre-specifiedEuro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): First-Line Participants

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.

Time frame:
Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C23, end of treatment (up to Week 107), follow-up (28 days after last dose)
Reported as:
Mean · units on a scale
Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): First-Line Participants
units on a scaleAxitinib (First-line Participants)Sorafenib (First-line Participants)
C1 D171.181 ± 19.64172.362 ± 16.466
C2 D171.714 ± 16.58372.422 ± 14.576
C3 D172.006 ± 16.97171.241 ± 16.252
C4 D172.179 ± 16.98072.086 ± 14.904
C5 D172.451 ± 18.23773.615 ± 14.665
C6 D171.574 ± 18.92969.944 ± 17.535
C7 D171.050 ± 18.96773.923 ± 13.998
C8 D171.031 ± 19.08173.183 ± 16.674
C9 D172.690 ± 18.78973.780 ± 16.180
C10 D172.910 ± 19.35472.400 ± 18.814
C11 D172.763 ± 18.17472.271 ± 18.512
C12 D173.610 ± 18.27575.295 ± 17.052
C13 D173.030 ± 18.34875.432 ± 17.907
C14 D173.147 ± 17.54675.108 ± 18.371
C15 D174.494 ± 17.93874.405 ± 17.650
C16 D173.878 ± 18.28975.818 ± 17.716
C17 D173.090 ± 17.71774.333 ± 18.654
C18 D173.817 ± 17.28875.571 ± 18.550
C19 D172.089 ± 18.16975.125 ± 20.919
C20 D174.244 ± 17.04474.190 ± 20.425
C21 D175.694 ± 11.91870.500 ± 21.637
C22 D178.000 ± 12.54473.917 ± 15.900
C23 D177.143 ± 12.69772.571 ± 14.820
End of treatment67.254 ± 19.49567.048 ± 22.570
Follow-up69.195 ± 20.36664.885 ± 19.916
Other pre-specifiedEuro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): Second-Line Participants

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0: worst imaginable health state to 100: best imaginable health state; higher scores indicate a better health state.

Time frame:
Baseline (Pre-dose on Cycle [C]1 Day [D]1), D1 of each cycle until C21, end of treatment (up to Week 103), follow-up (28 days after last dose)
Reported as:
Mean · units on a scale
Euro Quality of Life Questionnaire- 5 Dimensions (EQ-5D) Visual Analog Scale (VAS): Second-Line Participants
units on a scaleAxitinib (Second-line Participants)Sorafenib (Second-line Participants)
C1 D182.799 ± 13.35182.058 ± 14.021
C2 D181.102 ± 13.89578.231 ± 15.823
C3 D180.895 ± 13.38780.534 ± 16.453
C4 D181.138 ± 13.50881.245 ± 14.590
C5 D183.018 ± 12.82980.250 ± 15.495
C6 D182.222 ± 13.79380.829 ± 15.091
C7 D182.900 ± 13.28780.868 ± 16.140
C8 D183.382 ± 12.63681.000 ± 14.606
C9 D184.171 ± 11.26083.788 ± 10.349
C10 D183.041 ± 13.04282.778 ± 11.440
C11 D184.136 ± 14.23183.000 ± 11.832
C12 D184.305 ± 13.21183.500 ± 12.188
C13 D182.927 ± 17.31783.300 ± 11.263
C14 D186.520 ± 10.83186.667 ± 8.715
C15 D185.841 ± 11.78386.462 ± 8.678
C16 D187.579 ± 10.39186.083 ± 8.816
C17 D188.424 ± 10.86684.300 ± 10.328
C18 D186.586 ± 13.60583.125 ± 8.839
C19 D189.500 ± 8.68482.143 ± 11.495
C20 D190.333 ± 8.67986.000 ± 9.695
C21 D190.313 ± 9.74184.167 ± 9.704
End of treatment75.568 ± 17.93474.741 ± 17.623
Follow-up58.154 ± 20.76064.333 ± 25.564

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib (First-line Participants)117/173 (67.6%)77/173 (44.5%)161/173 (93.1%)
Sorafenib (First-line Participants)63/88 (71.6%)26/88 (29.5%)83/88 (94.3%)
Axitinib (Second-line Participants)9/11 (81.8%)6/11 (54.5%)11/11 (100%)
Sorafenib (Second-line Participants)3/5 (60%)3/5 (60%)5/5 (100%)
Most frequent serious events
Showing 10 of 108
Most frequent serious events
EventAxitinib (First-line Participants)Sorafenib (First-line Participants)Axitinib (Second-line Participants)Sorafenib (Second-line Participants)
AnaemiaBlood and lymphatic system disorders0/1731/883/111/5
Abdominal painGastrointestinal disorders1/1733/882/111/5
Anal fistulaGastrointestinal disorders1/1730/880/111/5
Multiple organ dysfunction syndromeGeneral disorders0/1730/880/111/5
Anal abscessInfections and infestations0/1730/880/111/5
Axonal and demyelinating polyneuropathyNervous system disorders0/1731/880/111/5
Cardio-respiratory arrestCardiac disorders2/1730/880/111/5
PneumoniaInfections and infestations4/1731/881/111/5
Disease progressionGeneral disorders20/1736/880/110/5
DiarrhoeaGastrointestinal disorders8/1732/881/110/5
Most frequent other events
Showing 10 of 147
Most frequent other events
EventAxitinib (First-line Participants)Sorafenib (First-line Participants)Axitinib (Second-line Participants)Sorafenib (Second-line Participants)
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders41/17331/884/114/5
DiarrhoeaGastrointestinal disorders88/17334/886/112/5
Back painMusculoskeletal and connective tissue disorders29/17314/886/110/5
ProteinuriaRenal and urinary disorders19/1739/886/110/5
HypertensionVascular disorders83/17328/884/111/5
Decreased appetiteMetabolism and nutrition disorders48/17316/885/110/5
ArthralgiaMusculoskeletal and connective tissue disorders28/17310/885/111/5
AstheniaGeneral disorders41/17315/885/110/5
Weight decreasedInvestigations70/17324/884/111/5
FatigueGeneral disorders55/17325/884/112/5

Baseline characteristics

Full analysis set (FAS) included all treatment-naive participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.

Age, Customized
Age, Customized(Participants)Axitinib (First-line Participants)Sorafenib (First-line Participants)Axitinib (Second-line Participants)Sorafenib (Second-line Participants)Total
Less than (<) 65 years1427711056385
Greater than or equal to (>=) 65 years50192513107
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib (First-line Participants)Sorafenib (First-line Participants)Axitinib (Second-line Participants)Sorafenib (Second-line Participants)Total
Female58224120141
Male134749449351
08

Study locations

125 sites
  • Advanced Medical Specialties
    Miami, Florida 33143, United States
  • Advanced Medical Specialties
    Miami, Florida 33176, United States
  • Illinois Cancer Specialists
    Arlington Heights, Illinois 60005, United States
  • Illinois Cancer Specialists
    Niles, Illinois 60714, United States
  • Indiana University Health Central Indiana Cancer Centers
    Carmel, Indiana 46032, United States
  • Indiana University Health Central Indiana Cancer Centers
    Fishers, Indiana 46037, United States
  • Indiana University Health Central Indiana Cancer Centers
    Greenfield, Indiana 46140, United States
  • Indiana University Health Central Indiana Cancer Centers
    Indianapolis, Indiana 46219, United States
  • Indiana University Health Central Indiana Cancer Centers
    Indianapolis, Indiana 46227, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114, United States
  • Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89052, United States
  • US Oncology West Region
    Henderson, Nevada 89052, United States
  • Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89074, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89128, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89148, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Hematology-Oncology Associates of Northern NJ, PA
    Morristown, New Jersey 07962, United States
  • Hematology-Oncology Associates of Northern NJ, PA
    Parsippany, New Jersey 07054, United States
  • New York Oncology Hematology, PC
    Albany, New York 12206, United States
  • New York Oncology Hematology, PC
    Albany, New York 12208, United States
  • New York Oncology Hematology, PC
    Latham, New York 12110, United States
  • New York Oncology Hematology, PC
    Rexford, New York 12148, United States
  • New York Oncology Hematology, PC
    Troy, New York 12180, United States
  • Raleigh Hematology Oncology Associates
    Cary, North Carolina 27518, United States
  • Raleigh Hematology Oncology Associates
    Raleigh, North Carolina 27607, United States
  • Raleigh Hematology Oncology Associates
    Raleigh, North Carolina 27614, United States
  • Northwest Cancer Specialists, PC
    Portland, Oregon 97213, United States
  • Northwest Cancer Specialists, PC
    Portland, Oregon 97225, United States
  • Northwest Cancer Specialists, PC
    Portland, Oregon 97227, United States
  • Northwest Cancer Specialists, PC
    Tualatin, Oregon 97062, United States
  • Penn State Milton S. Hershey Medical Center, Penn State Cancer Institute
    Hershey, Pennsylvania 17033-0850, United States
  • Medical University of South Carolina University Hospital
    Charleston, South Carolina 29425, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Texas Oncology- Amarillo
    Amarillo, Texas 79106, United States
  • Texas Oncology-Beaumont, Mamie McFaddin Ward Cancer Center
    Beaumont, Texas 77702-1449, United States
  • Texas Oncology- Bedford
    Bedford, Texas 76022, United States
  • Texas Oncology- Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Texas Oncology- Fort Worth 12th Avenue
    Fort Worth, Texas 76104, United States
  • Texas Oncology- Southwest Fort Worth
    Fort Worth, Texas 76132, United States
  • Investigational Products Center (lPC)
    Fort Worth, Texas 76177, United States
  • US Oncology Research and Clinical Pharmacy
    Fort Worth, Texas 76177, United States
  • Texas Oncology - Grapevine
    Grapevine, Texas 76051, United States
  • Cancer Care Centers of South Texas
    Kerrville, Texas 78028, United States
  • Texas Oncology- McAllen South Second Street
    McAllen, Texas 78503, United States
  • Texas Oncology- Midland Allison Cancer Center
    Midland, Texas 79701, United States
  • Cancer Care Centers of South Texas
    San Antonio, Texas 78217, United States
  • Cancer Care Centers of South Texas
    San Antonio, Texas 78258-3912, United States
  • Texas Oncology-Deke Slayton Cancer Center
    Webster, Texas 77598-4420, United States
  • Texas Oncology-Weslaco
    Weslaco, Texas 78596, United States
  • Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
    Christiansburg, Virginia 24073, United States
  • Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
    Low Moor, Virginia 24457, United States
  • Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
    Roanoke, Virginia 24014, United States
  • Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
    Salem, Virginia 24153, United States
  • Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
    Wytheville, Virginia 24382, United States
  • Northwest Cancer Specialists, PC
    Vancouver, Washington 98684, United States
  • Northwest Cancer Specialists, PC
    Vancouver, Washington 98686, United States
  • Wenatchee Valley Medical Center
    Wenatchee, Washington 98801, United States
  • Clinic of Oncology
    Banja Luka, 78000, Bosnia and Herzegovina
  • Institute of Oncology, University Hospital Center Sarajevo
    Sarajevo, 71000, Bosnia and Herzegovina
  • University Clinical Center Tuzla, Clinic for Oncology, Hematology and Radiotherapy
    Tuzla, 75000, Bosnia and Herzegovina
  • Spetsializirana Bolnitsa za Aktivno Lechenie po Onkologiya, EAD, Klinika po Himioterapiya
    Sofia, 1756, Bulgaria
  • SBALOZ D-r Marko Markov-Varna
    Varna, 9000, Bulgaria
  • Instituto Clinico Oncologico del Sur
    Temuco, Cautin 4810469, Chile
  • Instituto Clinico Oncologico del Sur
    Temuco, IX Region 4810561, Chile
  • Instituto de Terapias Oncologicas Providencia
    Providencia, Santiago 7501088, Chile
  • Private Office
    Santiago, RM 8360160, Chile
  • Cancer Institute and Hospital ,Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
  • Chinese PLA General Hospital
    Haidian District, Beijing 100853, China
  • The Fuzhou General Hospital, PLA Nanjing Military Area Command
    Fuzhou, Fujian 350025, China
  • Nanfang Hospital
    Guangzhou, Guang DONG 510515, China
  • Urology Department, Sun Yet-Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
  • Nanjing Bayi Hospital
    Nanjing, Jiangsu 210002, China
  • The Oncology Department, Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • Jilin Provincial Cancer Hospital
    Changchun, Jilin 130012, China
  • Urology Department, 1st Hospital of China Medical University
    Shen Yang, LIAO NING 110001, China
  • Xijing Hospital, The Fourth Military Medical University,Oncology Department
    Xi'an, Shaanxi 710032, China
  • Urology Department, Renji Hospital,Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200127, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology
    Hangzhou, Zhejiang 310016, China
  • Department of Urology,Peking University First Hospital
    Beijing, 100034, China
  • Beijing Cancer Hospital/Department of Renal Cancer and Melanoma
    Beijing, 100036, China
  • South-Western Hospital, 3rd Military Medical University
    Chongqing, 400038, China
  • Jiangsu Cancer Hospital
    Nanjing, 210009, China
  • Fudan University, Cancer Hospital, Department of Urology
    Shanghai, 200032, China
  • Tianjin Oncology Hospital,biology treatment department
    Tianjin, 300060, China
  • Urology Department, The Second Hospital of Tianjin Medical University
    Tianjin, 300211, China
  • BIBI General Hospital and Cancer Centre,
    Hyderabad, Andhra Pradesh 500024, India
  • Chinmaya Mission Hospital
    Bangalore, Karnataka 560038, India
  • Sri Venkateshwara Hospital
    Bangalore, Karnataka 560068, India
  • NU Hospitals
    Bangalore, Karnataka 560070, India
  • Cancer Care Clinic and Hospitals
    Nagpur, Maharashtra 440012, India
  • Shatabdi Superspeciality Hospital
    Nashik, Maharashtra 422 005, India
  • Curie Manavata Cancer Centre
    Nashik, Maharashtra 422004, India
  • Deenanath Mangeshkar Hospital and Research Centre
    Pune, Maharashtra 411 004, India
  • Sahyadri Speciality Hospital
    Pune, Maharashtra 411 004, India
  • Shettys hospital
    Bangalore, 560068, India
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
    Mexico, DF 14000, Mexico
  • Hospital General de Mexico O.D.
    Mexico City, Distrito Federal 06726, Mexico

Showing the first 100 of 125 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Rini BI, Atkins MB, Choueiri TK, Thomaidou D, Rosbrook B, Thakur M, Hutson TE. Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2021 Oct;19(5):e306-e312. doi: 10.1016/j.clgc.2021.03.019. Epub 2021 Apr 5. PubMed 33947608 ↗
  • de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21. PubMed 28410911 ↗
  • Hutson TE, Al-Shukri S, Stus VP, Lipatov ON, Shparyk Y, Bair AH, Rosbrook B, Andrews GI, Vogelzang NJ. Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial. Clin Genitourin Cancer. 2017 Feb;15(1):72-76. doi: 10.1016/j.clgc.2016.05.008. Epub 2016 May 27. PubMed 27498023 ↗
  • Grunwald V, Lin X, Kalanovic D, Simantov R. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Eur Urol. 2016 Dec;70(6):1006-1015. doi: 10.1016/j.eururo.2016.05.010. Epub 2016 May 26. PubMed 27238653 ↗
  • Qin S, Bi F, Jin J, Cheng Y, Guo J, Ren X, Huang Y, Tarazi J, Tang J, Chen C, Kim S, Ye D. Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study. Onco Targets Ther. 2015 Jun 8;8:1363-73. doi: 10.2147/OTT.S83302. eCollection 2015. PubMed 26089686 ↗
  • Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, Rosbrook B, Chen C, Kim S, Vogelzang NJ. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013 Dec;14(13):1287-94. doi: 10.1016/S1470-2045(13)70465-0. Epub 2013 Oct 25. PubMed 24206640 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2009 to primary completion in Jul 2012, 35 months.

Results were first posted in Feb 2014, 1 year 6 months after primary completion.

Of 22 phase 3 interventional studies under Kidney Neoplasms, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 89. This study's 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2009
First posted
Jun 15, 2009
StartActual
Aug 25, 2009
Primary completionActual
Jul 27, 2012
CompletionActual
Apr 29, 2021
Results first posted
Feb 4, 2014
Last update
May 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00920816
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 15, 2009
Start date
Aug 25, 2009
Primary completion
Jul 27, 2012
Completion
Apr 29, 2021
Results posted
Feb 4, 2014
Last update
May 6, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion